Clinical trial APHINITY
A randomised multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer.
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Academic trial | Non |
| Sponsor | Roche |
| EudraCT Identifier | 2010-02290-241 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT01358877 |
| Inclusion criteria | Non metastatic, operable HER2+ carcinoma of the breast |
| Last update |